ProfileGDS5678 / 1427548_a_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 87% 88% 88% 89% 87% 88% 88% 88% 89% 88% 89% 88% 89% 88% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 16.6875687
GSM967853U87-EV human glioblastoma xenograft - Control 26.9690788
GSM967854U87-EV human glioblastoma xenograft - Control 36.8303988
GSM967855U87-EV human glioblastoma xenograft - Control 47.1890189
GSM967856U87-EV human glioblastoma xenograft - Control 56.7997287
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 16.5561288
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 26.7257488
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 36.7687788
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 46.9157889
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 16.837688
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 27.0473189
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 36.8949488
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 47.0345889
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 56.8970788